# PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

> **NCT06274047** · PHASE3 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Androgen Axis Suppression
- Prostatectomy
- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Androgen Deprivation Therapy

## Key facts

- **NCT ID:** NCT06274047
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06274047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06274047, "PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06274047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*